Simcyp

Kyowa Hakko Kirin joins Certara’s Simcyp consortium

Wednesday, September 13, 2017

Certara, a provider of model-informed drug development and regulatory science, announced that Kyowa Hakko Kirin has joined the Simcyp Consortium and licensed the Simcyp Population-based Simulator. Kyowa Hakko Kirin is the 36th leading biopharmaceutical company and the 11th Japanese pharmaceutical company to join the Consortium. Member companies meet in a pre-competitive environment and work together to progress the evolution of modeling and simulation (M&S) and the Simcyp Simulator.

[Read More]

Certara launches Global Quantitative Systems Pharmacology Consortium

Wednesday, January 25, 2017

Certara, a provider of decision support technology and consulting services for optimizing drug development and improving health outcomes, is launching a Quantitative Systems Pharmacology (QSP) Immunogenicity Consortium. Modeled after Certara’s Simcyp Consortium, and believed to be the first of its kind, the QSP Immunogenicity Consortium brings together biopharmaceutical companies in a pre-competitive environment to cooperatively develop an Immunogenicity Simulator that will predict immunogenicity of biologics and its impact on their pharmacokinetics, efficacy and safety in diverse patient populations.

[Read More]

Certara, Paidion Research partner on pediatric drug development

Friday, September 11, 2015

Certara, a global biosimulation technology-enabled drug development company, and Paidion Research, a Durham, N.C.-based pediatric CRO, have partnered to promote more efficient and reliable drug development for pediatric patients. The partnership harnesses Certara’s biosimulation (modeling and simulation) and regulatory writing capabilities with Paidion’s regulatory strategy and pediatric clinical trial management expertise to address the critical challenges of bringing new therapies to children.

[Read More]

Certara launches Cardiac Safety Simulator

Thursday, August 1, 2013

St. Louis-based Certara, a provider of software and scientific consulting services to improve productivity and decision-making from drug discovery through drug development, has launched its Cardiac Safety Simulator (CSS), based on an in-silico model of human ventricular heart cells.

[Read More]